These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35052586)

  • 1. Vitamin B12 Reduces TDP-43 Toxicity by Alleviating Oxidative Stress and Mitochondrial Dysfunction.
    Jeon YM; Kwon Y; Lee S; Kim S; Jo M; Lee S; Kim SR; Kim K; Kim HJ
    Antioxidants (Basel); 2021 Dec; 11(1):. PubMed ID: 35052586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia.
    Montalbano M; McAllen S; Cascio FL; Sengupta U; Garcia S; Bhatt N; Ellsworth A; Heidelman EA; Johnson OD; Doskocil S; Kayed R
    Neurobiol Dis; 2020 Dec; 146():105130. PubMed ID: 33065281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DJ-1 Suppresses Cytoplasmic TDP-43 Aggregation in Oxidative Stress-Induced Cell Injury.
    Lei Y; Zhang ZF; Lei RX; Wang S; Zhuang Y; Liu AC; Wu Y; Chen J; Tang JC; Pan MX; Liu R; Liao WJ; Feng YG; Wan Q; Zheng M
    J Alzheimers Dis; 2018; 66(3):1001-1014. PubMed ID: 30372676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear transport dysfunction: a common theme in amyotrophic lateral sclerosis and frontotemporal dementia.
    Jovičić A; Paul JW; Gitler AD
    J Neurochem; 2016 Aug; 138 Suppl 1():134-44. PubMed ID: 27087014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration.
    Gao J; Wang L; Yan T; Perry G; Wang X
    Mol Cell Neurosci; 2019 Oct; 100():103396. PubMed ID: 31445085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both cytoplasmic and nuclear accumulations of the protein are neurotoxic in Drosophila models of TDP-43 proteinopathies.
    Miguel L; Frébourg T; Campion D; Lecourtois M
    Neurobiol Dis; 2011 Feb; 41(2):398-406. PubMed ID: 20951205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motor-Coordinative and Cognitive Dysfunction Caused by Mutant TDP-43 Could Be Reversed by Inhibiting Its Mitochondrial Localization.
    Wang W; Arakawa H; Wang L; Okolo O; Siedlak SL; Jiang Y; Gao J; Xie F; Petersen RB; Wang X
    Mol Ther; 2017 Jan; 25(1):127-139. PubMed ID: 28129109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of the Relative Contributions of Loss-of-function and Gain-of-function Mechanisms in TAR DNA-binding Protein 43 (TDP-43) Proteinopathies.
    Cascella R; Capitini C; Fani G; Dobson CM; Cecchi C; Chiti F
    J Biol Chem; 2016 Sep; 291(37):19437-48. PubMed ID: 27445339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of autophagy mitigates TDP-43 pathology and translational repression of neurofilament mRNAs in mouse models of ALS/FTD.
    Kumar S; Phaneuf D; Cordeau P; Boutej H; Kriz J; Julien JP
    Mol Neurodegener; 2021 Jan; 16(1):1. PubMed ID: 33413517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTK2/FAK regulates UPS impairment via SQSTM1/p62 phosphorylation in TARDBP/TDP-43 proteinopathies.
    Lee S; Jeon YM; Cha SJ; Kim S; Kwon Y; Jo M; Jang YN; Lee S; Kim J; Kim SR; Lee KJ; Lee SB; Kim K; Kim HJ
    Autophagy; 2020 Aug; 16(8):1396-1412. PubMed ID: 31690171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies.
    Jo M; Lee S; Jeon YM; Kim S; Kwon Y; Kim HJ
    Exp Mol Med; 2020 Oct; 52(10):1652-1662. PubMed ID: 33051572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes.
    Tan RH; Kril JJ; Fatima M; McGeachie A; McCann H; Shepherd C; Forrest SL; Affleck A; Kwok JB; Hodges JR; Kiernan MC; Halliday GM
    Brain; 2015 Oct; 138(Pt 10):3110-22. PubMed ID: 26231953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of TAR DNA-binding protein 43 (TDP-43) oligomers as initial intermediate species during aggregate formation.
    French RL; Grese ZR; Aligireddy H; Dhavale DD; Reeb AN; Kedia N; Kotzbauer PT; Bieschke J; Ayala YM
    J Biol Chem; 2019 Apr; 294(17):6696-6709. PubMed ID: 30824544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins.
    Ratti A; Buratti E
    J Neurochem; 2016 Aug; 138 Suppl 1():95-111. PubMed ID: 27015757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct targeting of TDP-43, from small molecules to biologics: the therapeutic landscape.
    Francois-Moutal L; Scott DD; Khanna M
    RSC Chem Biol; 2021 Aug; 2(4):1158-1166. PubMed ID: 34458829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolutionarily conserved heterogeneous nuclear ribonucleoprotein (hnRNP) A/B proteins functionally interact with human and Drosophila TAR DNA-binding protein 43 (TDP-43).
    Romano M; Buratti E; Romano G; Klima R; Del Bel Belluz L; Stuani C; Baralle F; Feiguin F
    J Biol Chem; 2014 Mar; 289(10):7121-7130. PubMed ID: 24492607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TDP-43 and Inflammation: Implications for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.
    Bright F; Chan G; van Hummel A; Ittner LM; Ke YD
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-nitrosylated TDP-43 triggers aggregation, cell-to-cell spread, and neurotoxicity in hiPSCs and in vivo models of ALS/FTD.
    Pirie E; Oh CK; Zhang X; Han X; Cieplak P; Scott HR; Deal AK; Ghatak S; Martinez FJ; Yeo GW; Yates JR; Nakamura T; Lipton SA
    Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33692125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid in vitro quantification of TDP-43 and FUS mislocalisation for screening of gene variants implicated in frontotemporal dementia and amyotrophic lateral sclerosis.
    Oyston LJ; Ubiparipovic S; Fitzpatrick L; Hallupp M; Boccanfuso LM; Kwok JB; Dobson-Stone C
    Sci Rep; 2021 Jul; 11(1):14881. PubMed ID: 34290285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained therapeutic benefits by transient reduction of TDP-43 using ENA-modified antisense oligonucleotides in ALS/FTD mice.
    Takeuchi T; Maeta K; Ding X; Oe Y; Takeda A; Inoue M; Nagano S; Fujihara T; Matsuda S; Ishigaki S; Sahashi K; Minakawa EN; Mochizuki H; Neya M; Sobue G; Nagai Y
    Mol Ther Nucleic Acids; 2023 Mar; 31():353-366. PubMed ID: 36817728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.